VANCOUVER, BRITISH COLUMBIA–(Marketwired – Jan. 13, 2017) – Valens GroWorks Corp. (CSE:VGWis pleased to announce the completion, by the Regional Inspectorate of the Office of Controlled Substances of Health Canada, of their final inspection of wholly-owned subsidiary Valens Agritech’s (“VAL“) 17,000 square foot R&D facility located in Kelowna, British Columbia.
The inspection is the final stage required to achieve licensing under our application for a Controlled Drugs and Substances Dealer’s Licence to enable the cultivation and processing of marijuana (such as creating extracts or derivatives) for the purpose of research, for processing manufacturing derivatives, and for transporting product to other locations (including related packaging, possession, sale, delivery and research activities).
Final pre-inspection preparation included the installation of significant enhanced physical security measures, the establishment of specified record keeping procedures, and the engagement of a Qualified Person In Charge (QPIC).
The Company is therefore pleased to announce Dr. Yasantha Athukorala, Ph.D. as the QPIC for VAL, as well as VAL’s Chief Scientific Officer. Dr. Athukorala is an accomplished scientist with outstanding research and leadership skills and more than 7 years of experience investigating bioactive compounds from agricultural bio-resources. With a unique background of Biotechnology, Chemistry and Bio-resource Technology knowledge, Dr. Athukorala brings a demonstrated record of project and publication success, credited with discovering naturally-occurring bioactive compounds using enzymatic digestion, bioassay-guided extraction and fractionation procedures with potential commercial applications in food, health and bio-resource utilization industries.
Dave Gervais, President of VAL., stated, “We warmly welcome Dr. Athukorala to the Valens team as we gear up to commence operations pending receipt of Health Canada’s Dealer’s Licence approval. Yasantha is a dedicated and creative scientist with superb transdisciplinary communication, relationship-building and team leadership attributes, and will be supported by a fully qualified alternate QPIC as we ramp up operations”.
About Valens GroWorks Corp.
The Company recently completed the acquisition of Valens Agritech Ltd. (“VAL“). VAL is a biotechnology company based in the Okanagan Valley of British Columbia, focused on cannabis cultivation and research, with assets and improvements that include a state-of-the-art 17,000 square foot R&D facility located in Kelowna, British Columbia.
Post-licensing, Valens anticipates participation in clinical trial programs researching the efficacy of medical cannabis for certain indications, and will also be seeking to capture a broad spectrum of medical marijuana users, as well as recreational users once legalized, in pursuit of its farm to pharma objectives.
On behalf of the Board of Directors,
VALENS GROWORKS CORP.
Robert van Santen, Chief Executive Officer
Cautionary statements
This press release contains forward-looking information based on current expectations. Statements about the Company’s expectations are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Valens Groworks assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek safe harbor.

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at “The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference”, a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

As a presenting sponsor, the Company will connect directly with some of the earliest moving investors in the psychedelic industry and reach an audience of 2,000+ investors. Presentations are 30 minutes in length, with 10 minutes allocated to a one-on-one Q&A session with the audience.

Keep reading... Show less

As Canadian operators race to strengthen their positions in the cannabis landscape, are international pursuits outside North America still top of mind?

The role that mergers and acquisitions (M&A) have played in the expansion of Canadian companies across the globe has been monumental for the growth of the cannabis industry. Now the space has reached a critical point as the demands of the US market increase.

Keep reading... Show less

It’s been just over a year since recreational cannabis was legalised in the Australian Capital Territory (ACT), home to the nation’s capital city of Canberra.

Announced on September 25, 2019, and brought into effect on January 31, 2020, the rules make it legal to possess and personally use small amounts of cannabis.

Keep reading... Show less

Pac Roots Cannabis Corp. (CSE: PACR) (“PacRoots” or the “Company”), announces the closing of its previously announced non-brokered private placement (see press release dated January 25, 2021).

Aggregate gross proceeds of $1,340,685.90 were raised through the issuance of 7,448,255 units (each a “Unit”). Each Unit consists of one common shares and one share purchase warrant. Each warrant is exercisable at a price of $0.30 per share until February 23, 2024.

Keep reading... Show less

 Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States will release its fourth quarter 2020 financial results on Tuesday, March 23, 2021 before markets open. Following the earnings release, management will host a conference call at 8:30 AM Eastern Time to review the financial results.

All interested parties can join the conference call by dialing 1-888-231-8191 or 1-647-427-7450, conference ID: 7066881. Please dial in 15 minutes prior to the call to secure a line. The conference call will be archived for replay until March 30, 2021 . To access the archived conference call, please dial 1-855-859-2056 and enter the encore code 7066881.

Keep reading... Show less